Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer

Journal of Thoracic Disease

Volumn 5, Issue 5, 2013, Pages 618-625

  Healey, Graham F ^a   Lam, Stephen ^b   Boyle, Peter ^c   Hamilton fairley, Geoffrey ^a   Peek, Laura J ^d   Robertson, John F R ^e  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d Oncimmune Germany GmbH   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Autoantibody (AAb); Lung cancer; Risk stratification; Tumor associated antigen

Indexed keywords

AUTOANTIBODY; CAGE PROTEIN; GBU4 5 PROTEIN; HUD PROTEIN; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; PROTEIN P53; TRANSCRIPTION FACTOR SOX2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER TEST; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; HEALTH PROGRAM; HUMAN; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84888323895     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.08.65     Document Type: Article

References (10)

1. Murray A, Chapman CJ, Healey G, et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol 2010;21:1687-1693.
2. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-389.
3. Chapman CJ, Healey GF, Murray A, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33:1319-1326.
4. Lam S, Boyle P, Healey GF, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) 2011;4:1126-1134.
5. Armitage P, Berry G, Matthews JNS. Analysing means and proportions. In: Statistical methods in medical research, 4th edition. Oxford: John Wiley and Sons, 2001:83-146.
6. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.
7. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
8. Pepe MS. eds. The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press, 2003.
9. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011;103:1058-1068.
10. Taiwo EO, Yorio JT, Yan J, et al. How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience. PLoS One 2012;7:e52313.